Brief: AB Science: Results From Phase 3 Study Evaluating Masitinib In Prostate Cancer
26/05/2021 18:24
May 26 (Reuters) - AB Science SA ABS.PA :
* NEW PATENT WAS FILED BASED ON RESULTS FROM STUDY AB12003,
WHICH
WOULD PERMIT AB SCIENCE TO RETAIN EXCLUSIVE RIGHTS ON USE OF
MASITINIB IN PROSTATE CANCER UNTIL 2042
* AB SCIENCE COMMUNICATES RESULTS FROM PHASE 3 STUDY
EVALUATING
MASITINIB IN PROSTATE CANCER
Source text for Eikon: ID:nGNE5G7pVP
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease